Pre-Open Stock Movers 2/25: (MNK) (LL) (MRNA) Higher (TUP) (PANW) (SHAK) Lower (more...)

Go back to Pre-Open Stock Movers 2/25: (MNK) (LL) (MRNA) Higher (TUP) (PANW) (SHAK) Lower (more...)

Kratos Defense (KTOS) Secures $11.5M Contract to Build Advanced Space Radio Monitoring System to Assure Satellite Spectrum

February 27, 2020 9:02 AM EST

Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) announced today that it was awarded an $11.5 million contract to build an advanced space radio monitoring system for a government customer. The system will incorporate Kratos technologies and integrated products to help the country regulate and protect the satellite spectrum.

As part of the multi-million dollar project, Kratos is responsible for the turnkey design, installation and... More

Perrigo (PRGO) Misses Q4 EPS by 1c; Offers FY20 EPS Guidance Below Consensus

February 27, 2020 6:36 AM EST

Perrigo (NYSE: PRGO) reported Q4 EPS of $1.06, $0.01 worse than the analyst estimate of $1.07. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.31 billion.

Key Fourth Quarter Financial Highlights

GAAP ("reported") consolidated fourth quarter net sales were $1.3 billion, an increase of 10.7% compared to the prior year quarter. Adjusted net sales(1) increased 13.4% compared to the prior year quarter, excluding currency(2).Worldwide Consumer fourth quarter reported net sales increased 12.7% compared to the prior year quarter. Worldwide Consumer adjusted net sales increased 16.4% versus the fourth quarter of 2018, excluding currency.Consumer... More

Kratos Defense (KTOS) Secures Contract from Northrop Grumman (NOC) to Support U.S. Air Force Ground Based Strategic Deterrent Program

February 26, 2020 8:14 AM EST

Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a leading National Security Solutions provider, announced today that its Command, Control, Communications, Computing, Combat & Intelligence, Surveillance and Reconnaissance (C5ISR) Division has been... More

Moderna (MRNA) Tops Q4 EPS by 5c

February 26, 2020 7:16 AM EST

Moderna (NASDAQ: MRNA) reported Q4 EPS of ($0.37), $0.05 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $14.06 million versus the consensus estimate of $17.37 million.

The Moderna team continues to execute our strategy, including our CMV Phase 2 study enrolling ahead of plan,... More

Endo International (ENDP) Tops Q4 EPS by 17c, Revenues Beat; Provides FY20 EPS/Revenue Outlook

February 26, 2020 6:06 AM EST

Endo International (NASDAQ: ENDP) reported Q4 EPS of $0.74, $0.17 better than the analyst estimate of $0.57. Revenue for the quarter came in at $764.8 million versus the consensus estimate of $731.43 million.

Total revenues during the fourth quarter of 2019 were $765 million, a decrease of 3% compared to fourth-quarter 2018 revenues of $786 million.Revenues of the Specialty Products portfolio of Branded Pharmaceuticals segment increased 15% in the fourth quarter of 2019 to $149 million compared to fourth-quarter 2018 revenues of $130 million.Revenues of the Sterile Injectables segment increased 10% in the fourth quarter of 2019 to $285 million compared to fourth-quarter 2018 revenues of $259... More